Application of fluorinated camptothecin compound in prevention and treatment of bladder cancer
By introducing fluorine atoms into the camptothecin molecule, fluorinated camptothecin compounds were developed, which solved the problem that existing bladder cancer treatment drugs are not sensitive to some tumor cells. Fluorinated camptothecin compounds showed excellent anti-tumor activity, especially W-16, which had the lowest IC50 value against bladder cancer cells and has significant therapeutic potential.
Patent Information
- Application Number
- CN202411049819.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-12
AI Technical Summary
Existing bladder cancer treatments are insensitive to some tumor cells, leading to recurrence, and systemic chemotherapy regimens have low response rates. There is a need to develop new drugs that target different sites of action to improve the overall tumor response rate.
By introducing fluorine atoms into the A ring of camptothecin, a series of fluorinated camptothecin compounds were developed. These compounds were then used to intervene in bladder cancer T24 and umuc3 cell lines. Cell viability was measured, IC50 values were calculated, and compounds with high inhibitory activity were screened out.
Fluorinated camptothecin compounds have shown significantly superior antitumor activity compared to existing drugs. In particular, W-16 has the lowest IC50 value against bladder cancer cells, demonstrating strong killing ability and promising therapeutic potential.
Smart Images

Figure BDA0004974596780000021 
Figure BDA0004974596780000031 
Figure BDA0004974596780000041
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine and discloses a new use of a fluorinated camptothecin compound - anti-bladder cancer activity, which is used for preparing a drug for treating bladder cancer. Background Art
[0002] Bladder cancer is one of the common malignant tumors of the urinary system, with the characteristics of easy recurrence and rapid progression, and chemotherapy-based treatment methods occupy a key position in the treatment of bladder cancer. Chemotherapy mainly includes intravesical chemotherapy and systemic chemotherapy. Intravesical chemotherapy is mainly used for intravesical instillation of non-muscle-invasive bladder cancer after surgery to prevent tumor recurrence. However, due to the heterogeneity of tumors, some tumors are insensitive to drugs, leading to recurrence. The mainstream strategy of systemic chemotherapy is the platinum-based cisplatin combined with gemcitabine (GC) regimen, which has an overall response rate of 49%, but about half of the patients do not respond to this regimen. In view of the differences in the sensitivity of bladder cancer cells to existing drugs, it is particularly important to develop and apply new drugs targeting different sites of action to improve the overall tumor response rate.
[0003] Fluorine atoms are considered to be potential bioisosteres of hydrogen atoms, carbonyl groups, sulfonyl groups, and cyano groups due to their unique physical and chemical properties, and are often considered a master key by the pharmaceutical industry. From a molecular level, the acidity, lipophilicity, electrostatic interactions, and metabolic processes of fluorinated compounds in the body will be regulated or even changed; at a physiological level, the introduction of fluorine atoms into drug molecules can improve bioavailability, increase selectivity for target organs, and reduce the dosage of drugs. The characteristics of the fluorine element give fluorinated compounds unique physical and chemical properties, which has promoted the rapid development of fluorinated drugs.
[0004] Camptothecin is a pentacyclic quinoline alkaloid isolated from the bark and stem of Camptotheca acuminata and is one of the important lead compounds in the development of anticancer drugs. Currently, camptothecin-derived DNA topoisomerase I inhibitors such as topotecan, irinotecan and belotecan have been approved for the treatment of non-small cell lung cancer, ovarian cancer and colorectal cancer, but are still rarely used in bladder cancer. The structure-activity relationship of camptothecin shows that modification of the A ring can significantly affect its antitumor activity and is the best site for the in-depth development of new highly active molecules.
[0005] Therefore, we used camptothecin as the lead structure, introduced fluorine atoms in the A ring, obtained a series of A ring fluorinated camptothecin compounds, and tested their inhibitory activity against bladder cancer T24 and umuc3 cell lines. The experimental results further revealed that fluorinated camptothecin compounds can be developed as a new type of anti-bladder cancer drug, and the compounds described in the present invention have not yet been used in the treatment of bladder cancer. Summary of the invention
[0006] The purpose of the present invention is to provide an anti-bladder cancer activity of a fluorinated camptothecin compound, in order to prepare a drug for treating bladder cancer.
[0007] The following experiment involved intervention in bladder cancer T24 and umuc3 cell lines, and used the CCK-8 method to determine the cell survival rates of T24 and umuc3 cells with different intervention concentrations, in order to specifically study and analyze the anti-bladder cancer activity of fluorinated camptothecin compounds.
[0008] The fluorinated camptothecin compounds provided by the present invention are all dissolved and diluted in DMSO to form a 10mM stock solution, and gradiently diluted in RPMI-1640 complete medium as a solvent to form 8μM, 1.6μM, 0.32μM, 0.064μM, 0.0128μM, 0.00256μM, 0.000512μM, 0.0001024μM, 0.00002048μM, and 0.000004096μM working solutions. The cell survival rates of T24 and umuc3 cells with different concentrations of intervention were determined by CCK-8 method, and the half inhibitory concentration (IC50) of each compound in different cells was calculated and fitted according to the cell survival rate. 50 ) value, IC 50 The lower the concentration, the fewer cells survive at the same concentration, which means the stronger the ability to kill tumor cells.
[0009] The bladder cancer cell lines T24 and umuc3 used were cultured in RPMI-1640 complete medium (RPMI-1640 basal medium, 10% fetal bovine serum, penicillin / streptomycin double antibody) at 37° C., 5% carbon dioxide and saturated humidity.
[0010] T24 and umuc3 cells in logarithmic growth phase were digested with trypsin and prepared into single cell suspension using RPMI-1640 complete medium. After counting, they were inoculated into 96-well plates at a density of 5000 cells / well. After the cells adhered to the wall, the culture medium was removed and 100ul / well of the above working solution was added to the plate. Three replicate wells were set up in each group. After 72h of intervention, the working solution was removed and 100ul of RPMI-1640 basal medium containing 5% CCK-8 reagent was added to each well. After further culturing for 2h, the absorbance of each well was measured by a microplate reader at a wavelength of 450nm. The cell inhibition rate and IC were calculated based on the absorbance. 50 The results were compared with cisplatin, a commonly used drug for bladder cancer treatment, and the commercial camptothecin drugs topotecan and irinotecan.
[0011] Each compound was tested three times. The structural formula of the fluorinated camptothecin compound and its IC in bladder cancer cells 50 See Table 1.
[0012] Table 1 Structural formula of fluorinated camptothecin compounds and their IC in bladder cancer cells 50 data
[0013]
[0014]
[0015]
[0016]
[0017]
[0018] The experimental results in Table 1 show that all the fluorinated camptothecin compounds involved showed strong inhibitory activity against bladder cancer T24 and umuc3 cell lines. Among them, W-16 had the best activity, with an IC of 1.17 and 1.20 for bladder cancer T24 and umuc3 cell lines. 50 The values were 0.000307uM and 0.000291uM, respectively, which were significantly better than the control drugs cisplatin, topotecan and irinotecan. In addition, W-1, W-2, W-3, W-5, W-6, W-8, W-11, W-12, W-13, W-15 and W-18 also showed anti-tumor activity better than or close to the control drugs on bladder cancer T24 and umuc3 cell lines. And W-4, W-7, W-9, W-14, W-17 and W-19 showed an inhibitory effect better than irinotecan on the two bladder cancer cell lines tested. Therefore, the fluorinated camptothecin compounds involved in the present invention have good application prospects in the treatment of bladder cancer.
[0019] Based on the above research results, fluorinated camptothecin compounds are used as active substances, and pharmaceutically acceptable carriers and / or excipients are added in the form of pharmaceutically acceptable salts to prepare any pharmaceutically acceptable dosage form, such as tablets, sprays, granules, capsules, oral solutions, injections, and suspensions.
Claims
1. Use of fluorinated camptothecin compounds as active ingredients in the preparation of anti-bladder cancer drugs, characterized in that: The structural formula of the fluorinated camptothecin compound is as follows:
2. The use of the fluorinated camptothecin compound as claimed in claim 1 as an active ingredient in the preparation of an anti-bladder cancer drug, characterized in that: The fluorinated camptothecin compound or a pharmaceutically acceptable salt thereof is added with a pharmaceutically acceptable carrier and / or auxiliary material to prepare any pharmaceutically acceptable dosage form.
3. Use of the fluorinated camptothecin compound as claimed in claim 2 as an active ingredient in the preparation of an anti-bladder cancer drug, characterized in that: The dosage form is any one of tablets, sprays, granules, capsules, oral liquids, injections, and suspensions.
Citation Information
Cited By
Preparation of 10-trifluoromethoxy camptothecin derivative and application of 10-trifluoromethoxy camptothecin derivative in anti-tumor aspect
CN119350354A
Preparation of a 10-trifluoromethoxycamptothecin derivative and its use in antitumor therapy
CN119350354B
Preparation of trifluoromethyl camptothecin derivative and application of trifluoromethyl camptothecin derivative in anti-tumor aspect
CN119350355A
Preparation of a trifluoromethyl camptothecin derivative and its use in the fight against tumors
CN119350355B
